Skip to main content

Uterine (Including Endometrial) Cancer Clinical Trials

Review the uterine (including endometrial) cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 312

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Status: Active
Location: See ClinicalTrials.gov
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Status: Active
Location: See ClinicalTrials.gov
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
ALG.APV-527 First-in-human Study
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
Status: Active
Location: See ClinicalTrials.gov
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
Status: Active
Location: See ClinicalTrials.gov
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
Status: Active
Location: See ClinicalTrials.gov
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Status: Enrolling by Invitation
Location: 4 locations
Curcumin for the Treatment of Patients with Cervical Intraepithelial Neoplasia
Status: Approved
Location: Grady Health System, Atlanta, Georgia
Telaglenastat and Chemoradiotherapy for the Treatment of Advanced Cervical Cancer
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Standard Dose Fractionation Regimens for Vaginal Brachytherapy in Treating Sexual Dysfunction in Patients with Stage I-II Endometrial Cancer After Surgery
Status: Temporarily Closed to Accrual
Location: 3 locations
Immunotherapy (MGD019) Treatment for Recurrent, Metastatic, or Persistent Cervical Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Vudalimab for the Treatment of Advanced Rare Cancers
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Selumetinib and Olaparib in Treating Participants with Relapsed or Refractory and Advanced Endometrial, Ovarian, or Other Solid Tumors with RAS Pathway Alterations
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Status: Active
Location: 45 locations
Distance-Based Exercise to Preserve Function and Prevent Disability (DEFEND)
Status: Active
Location: 17 locations